RE:RE:Shelf OfferingNero,
Partnership is a desired objective. There was no other reason to structure the IP section of Nextleaf as a semi-separate 100% held entity. Some half of it is ready for grab. Didn't work so far with cannabis, might work with both cannabis + psychedelics.
The key word in today press release is "mirror'. They intend to "mirror" i.e. duplicate for mushrooms what they did for cannabis. They already have most of the technology and IP. This could be huge.
Duplication will cost money, hence the shelf prospectus. If they can make it by selling shares at say 50-70 cents it would be a good thing. If they sell a debenture (as they did in the past) no problem. But a partner, bringing in capacity and markets, would be great.
Some on this board are dreaming about a takeover. It could end up being a merge with, say, Valens, on the basis of $1 of Valens share for a Nextleaf share. This industry is prone to partnerships and consolidation.